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The results of the combined use of Fludarabine, an anticancer agent that may be able to target latently infected cells, and
conventional antiretroviral therapy (AZTDDI) in a murine model of AIDS, i.e., LP-BM5 infection, are reported. Eighty percent
of infected mice, treated with four cycles of alternate administration of Fludarabine and AZTDDI, showed undetectable
levels of proviral DNA in lymph nodes. After 8 weeks of treatment interruption, the infected/treated animals, although still
alive at a time when all untreated animals had succumbed to the infection, showed disease progression and reappearance
of proviral DNA in lymph nodes. The retrospective analysis of proviral DNA content in spleen and bone marrow at the end
of the fourth cycle of treatment revealed a low but detectable amount of BM5d proviral DNA. We thus concluded that the
spleen and bone marrow may be less sensitive to lympholitic drugs and therefore act as viral reservoirs in LP-BM5 infection.
This study suggests that optimized protocols of alternate administration of cytolytic and antiretroviral drugs may representINTRODUCTION
It is generally accepted that highly active antiretroviral
therapy (HAART) is not able to eradicate HIV-1 infection
due to its limited effects on viral reservoirs carrying
replication-competent HIV (Chun and Fauci, 1999; Chun
et al., 1999; Finzi et al., 1999; Pierson et al., 2000). This
observation has led many researchers to investigate a
wide range of alternative antiviral strategies that include
immunomodulant agents such as cyclosporin A or drugs
that target HIV entry by blocking its binding to the core-
ceptors CCR5 and CXCR4 (D’Souza et al., 2000; Franchin
et al., 2000; Rizzardi et al., 2000; Strizki et al., 2001). In
addition, increased attention has been paid to therapeu-
tic approaches aimed at reducing or eliminating the
latent reservoirs of HIV and the fact that macrophages
are also important reservoirs in HIV-infected patients
(Chun et al., 2000; Igarashi et al., 2001; Lambotte et al.,
2000) suggests that strategies targeting only the pool of
latently infected CD4 T cells will not be sufficient to
eradicate HIV-1 infection. From this perspective, an ideal
anti-HIV-1 therapy should include drugs that protect new
1 To whom correspondence and reprint requests should be ad-
dressed at Istituto di Chimica Biologica “G. Fornaini”, Universita` degli© 2002 Elsevier Science (USA)
All rights reserved.cells from infection (i.e., conventional HAART) and
agents that reduce the pool of latently infected cells.
Based on these assumptions, we have evaluated in a
murine model of AIDS (Jolicoeur, 1991; Morse et al., 1992)
the efficacy of a new therapeutic protocol that includes
the anticancer drug Fludarabine in combination with
conventional antiretroviral drugs. Murine AIDS (MAIDS)
is induced by a replication-defective virus (BM5d). In
susceptible mice (C57BL/6), inoculation with LP-BM5
murine leukemia viruses, which consist of the BM5d
virus and replication-competent B-tropic ecotropic
(BM5e) and the mink cell focus-inducing (BM5-MCF)
helper viruses, results in polyclonal proliferation of T and
B cells, immunodeficiency, and expansion of B cells
containing the BM5d provirus followed by the develop-
ment of B cell lymphomas. The defective virus compo-
nent in the LP-BM5 mixture can be integrated latently in
infected cells and expressed only upon infection of the
BM5e. Therefore, since the pathogenic component of the
LP-BM5 is a defective virus, both lymphocytes and mac-
rophages can be infected in a nonproductive way.
Fludarabine is a nucleoside analogue used in the
treatment of hematological malignancies (Keating et al.,
1989). Unlike most chemotherapeutic agents, which are
active in rapidly proliferating cells but not in resting cells,
Fludarabine appears to be active both in resting and ina useful strategy to eradicate retroviral infections. © 2002
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activated cells. In activated cells Fludarabine exerts its
cytotoxic action by incorporation in genomic DNA, while354Elsevier
pholiti
in resting cells it induces cell death by mechanisms such
as inhibition of RNA transcription, depletion of ATP, and
inhibition of STAT1 signaling (Dighiero, 1996; Frank et al.,
1999; Huang et al., 2000; Robertson et al., 1993). In a
series of earlier experiments we first determined the
concentration of Fludarabine that was most effective in
reducing the progression of LP-BM5-induced murine
AIDS and proviral DNA content; then we tested the effi-
cacy of the alternate administration of Fludarabine and
AZT (Fraternale et al., 2000a,b). Here we report the re-
sults relative to a study of alternate administration of
Fludarabine and two nucleoside analogues (AZT plus
DDI). Although full eradication of infection was not
achieved with this protocol, the fact that repeated cycles
of Fludarabine and nucleoside analogues consistently
reduced the lymph node proviral DNA content to unde-
tectable levels represents a significant improvement
when compared to previous approaches.
RESULTS
Study design
LP-BM5-infected mice were used to evaluate a new
therapeutic protocol based on alternate cycles of Flu-
darabine and AZT plus DDI aimed at eradicating viral
infection by targeting latently infected cells. The treat-
ment protocol is described in Fig. 1. Every cycle included
2 weeks of treatment with Fludarabine followed by 2
weeks of treatment with AZT and DDI. At the end of each
treatment cycle, five infected mice, five infected/treated
mice, and five uninfected/untreated mice were sacrificed
and evaluated for the presence of splenomegaly, lymph-
adenopathy, and hypergammaglobulinemia, as well as
for the level of proviral DNA content in lymph nodes.
Alternate administration of Fludarabine and AZT plus
DDI reduces the LP-BM5-associated splenomegaly,
lymphadenopathy, and hypergammaglobulinemia
To determine the effect of our protocol of alternate
administration of Fludarabine and AZT plus DDI, we first
obtained measures of the standard markers of disease
progression in LP-BM5-infected mice. The results of the
evaluation of splenomegaly, lymphadenopathy, and hy-
pergammaglobulinemia are reported in Table 1. It should
first be noted that after one cycle (4 weeks postinfection,
p.i.) and two cycles (8 weeks p.i.) of treatment all three
parameters were already significantly reduced in in-
fected/treated mice as compared to infected/untreated
mice. However, at these times after initiation of treatment
all measured markers of disease progression were still
increased when compared to uninfected mice. Impor-
tantly, further cycles of Fludarabine and AZT plus DDI
were able to induce a normalization of the studied pa-
rameters, so that after three (12 weeks p.i.) and four (16
weeks p.i.) cycles the assessment of splenomegaly,
lymphadenopathy, and hypergammaglobulinemia indi-
cated values that were undistinguishable from those of
uninfected control mice. In all, these results suggest that
repeated cycles of Fludarabine and AZT plus DDI induce
a significant delay in the clinical progression of LP-BM5
infection.
Alternate administration of Fludarabine and AZT plus
DDI normalizes the LP-BM5-associated changes in
the relative proportions of peripheral blood
lymphocytes
LP-BM5 disease progression is associated with sig-
nificant changes in the relative proportion of peripheral
blood lymphocytes (PBLs), including increase of both
CD4 and CD8 T cells, and marked decline of CD19 B
cells (Fraternale et al., 1999). The LP-BM5-induced im-
munological changes are considered an important
marker of disease progression and their measurement
may be used to evaluate the efficacy of a new antiretro-
viral therapy. To determine the effect of our therapeutic
protocol on the immunophenotype of PBLs, we have
performed a sequential study of the relative proportion of
CD90.2, CD4, CD8, and CD19 cells. As shown in
Fig. 2, and consistent with our previous articles (Frater-
nale et al., 1999), LP-BM5 infection caused an increase in
the percentage of CD8 and CD4 T cells (and conse-
quently in the percentage of total CD90.2 T cells) and a
decrease in the percentage of B cells. After initiation of
treatment, we observed a progressive normalization of
the PBL immunophenotype (not shown), and by 8 weeks
after the completion of the fourth cycle (24 weeks) all
immunological parameters were comparable to those
observed in uninfected mice (Fig. 2). The evaluation of
the same parameters in the infected/untreated mice was
not possible at the 24 week postinfection time point
since by then all infected/untreated animals had suc-
cumbed to the disease.
In summary, this set of results indicates that repeated
cycles of alternate Fludarabine and AZT plus DDI admin-
istration may normalize the LP-BM5-induced changes in
the peripheral blood immunophenotype.
Mitogenic response of splenocytes
As reported previously (Fraternale et al., 2000a), LP-
BM5 infection induces a defective proliferative response
to mitogens in splenocytes. This proliferative response
can be partly restored by antiretroviral therapy with FLU-
DARABINE darabine and AZT (Fraternale et al., 2000a).
To determine the effect of our therapeutic protocol on the
proliferative response of B splenocytes to the mitogenic
agent lipopolysaccharides (LPS), we have performed se-
rial measurements at 12 and 16 weeks p.i. (after three
and four cycles of treatment) and 8 weeks after treatment
interruption (3rd cycle8 weeks and 4th cycle8
weeks). We focused on the proliferative response of B
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lymphocytes since the number of these cells appeared to
be most consistently affected by Fludarabine administra-
tion. As shown in Fig. 3, Fludarabine-treated animals
experienced a defective proliferative response to LPS
that was more evident when the experiments were car-
ried out at the end of the therapeutic cycle. However, an
8-week treatment interruption was sufficient to partially
reestablish proliferative responses. In all, these results
indicate that the LP-BM5-associated functional defects
of B lymphocytes are reversible and B cells return to a
near-normal response to LPS after three or four cycles of
alternate Fludarabine/AZTDDI treatment.
Alternate Fludarabine and AZT plus DDI may
decrease LP-BM5 proviral DNA content in lymph
nodes below detectable limits
The measurement of proviral DNA content in lymphoid
tissues is generally considered the most reliable index of
disease progression in LP-BM5-infected mice. To deter-
mine the effect of our therapeutic protocol on the level of
ongoing viral replication in LP-BM5-infected mice, we
measured proviral DNA in lymph nodes at weeks 4, 8, 12,
and 16 p.i. using a competitive PCR assay with a sensi-
tivity of 100 copies of proviral DNA as described under
Materials and Methods. It is of note that in LP-BM5
infection, MAIDS develops as a lymphoproliferative dis-
order and therefore the inclusion of Fludarabine in a
therapeutic protocol may reduce the overall level of viral
replication simply by reducing the number of proliferating
lymphocytes with integrated proviral DNA. To partly cor-
rect for this nonspecific effect of Fludarabine, we have
always measured the copy numbers per fixed amount of
cellular DNA (i.e., 40 ng). As shown in Table 2, the
proviral DNA content in lymph nodes significantly de-
creased in treated animals at week 4, 8, and 12 postin-
fection. Notably, at week 16 postinfection the proviral
DNA in lymph nodes was undetectable in four of five
(80%) treated animals. These results represent the first
instance of a near-complete suppression of LP-BM5 viral
replication in lymph nodes following an antiretroviral
protocol involving alternate administration of classical
antiretroviral drugs and Fludarabine. Furthermore, these
findings represent a significant improvement when com-
pared to the results obtained using less aggressive treat-
ment protocols in which the proviral DNA in lymph nodes
was detectable throughout the follow-up time and
showed only an 85% decrease compared to infected/
untreated controls (Fraternale et al., 2000a).
Evidence of reactivation of LP-BM5 infection is
observed 8 weeks after interruption of the alternate
Fludarabine and AZT plus DDI treatment
The decline of the proviral DNA level below the de-
tectable limit of our assay is an interesting result but
does not in itself indicate that eradication of the infection
has been achieved. To determine the duration of viral
suppression that follows repeated cycles of Fludarabine
and AZT plus DDI therapy we have performed analysis of
proviral DNA content in lymph nodes from animals after
eight weeks of treatment interruption, after either three or
four cycles of therapy. As shown in Fig. 4, after 8 weeks
of interruption, evidence of infection was found in the
TABLE 1
Reduction of Splenomegaly, Lymphadenopathy, and Hypergammaglobulinemia in C57BL/6 Mice Infected
with LP-BM5 After Alternate Administration of Fludarabine and AZT Plus DDI
Experimental group Weeks p.i. Spleen weight (g) Lymph node weight (g) IgG (mg/100 ml)
Control (C) 4 (1st cycle) 0.08 0.01 0.04 0.01 103 9
Untreated (I) 4 (1st cycle) 0.17 0.04 0.17 0.08 314 124
Treated (T) 4 (1st cycle) 0.19 0.07 0.03 0.01a 121 38a
C 8 (2nd cycle) 0.07 0.01 0.03 0.01 132 8
I 8 (2nd cycle) 0.37 0.12 0.96 0.57 902 300
T 8 (2nd cycle) 0.15 0.10a 0.07 0.04a 201 111a
C 12 (3rd cycle) 0.08 0.03 0.03 0.01 75 22
I 12 (3rd cycle) 1.38 0.26 5.31 0.73 542 16
T 12 (3rd cycle) 0.13 0.04a 0.03 0.01a 85 46a
C 20 (3rd cycle  8) 0.12 0.02 0.04 0.01 131 10
T 20 (3rd cycle  8) 0.20 0.07a 0.27 0.14 193 104a
C 16 (4th cycle) 0.14 0.04 0.04 0.00 133 4
I (n 2)b 16 (4th cycle) 0.51; 0.34 3.30; 3.70 292; 307
T 16 (4th cycle) 0.05 0.02 0.01 0.00 70 8
C 24 (4th cycle  8) 0.13 0.02 0.05 0.01 160 41
T 24 (4th cycle  8) 0.25 0.10a 0.40 0.21 425 182
Note. Values are mean  standard deviation of five animals.
a Not significantly different vs control.
b Three animals died as a consequence of the infection. At 20 and 24 weeks p.i. the values relative to infected/untreated mice are not reported since
all animals had died. The treatment protocol is represented in Fig. 1.
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lymph nodes of all the examined animals (18,020 
14,660 and 11,968  6755 LP-BM5d copy number/40 ng
of total cellular DNA at the 3rd  8 and 4th  8 cycle,
respectively). These results indicate that LP-BM5 infec-
tion was in fact not eradicated in the treated mice and
that the inability to detect proviral DNA in lymph nodes
after the fourth cycle did not reflect eradication of infec-
tion.
Ongoing LP-BM5 replication in spleen and bone
marrow may represent the source of rebound viremia
after discontinuation of therapy
The observation of a rebound of viral replication after
discontinuation of therapy is consistent with the pres-
ence of anatomic/cellular sites that act as endogenous
reservoirs for the infection. To determine the potential
source of the observed viral rebound after discontinua-
tion of therapy, we examined the proviral DNA content in
spleen and bone marrow of animals that were sacrificed
after four cycles of alternate Fludarabine and AZT plus
DDI administration. As shown in Table 3, the presence of
proviral BM5d-DNA is detectable in both the spleen and
the bone marrow of all tested animals. Although this
level of ongoing viral replication is significantly lower
FIG. 2. Immunophenotype of peripheral blood lymphocytes from control (F), infected/untreated (), and infected/treated animals (Œ) at various time
points postinfection. The treatment protocol is shown in Fig. 1. Values are mean  standard deviation of five animals and are expressed as
percentages of the total lymphocyte population. At the time of the fourth cycle (16 weeks p.i.) the values of only two infected animals are reported
because three mice had died as a consequence of the infection. After 8 weeks of fourth-cycle interruption (4th cycle8, 24 weeks p.i.), the values
relative to the infected/untreated mice are not reported since all animals had died.
FIG. 3. B-lymphocyte proliferative response to lipopolysaccharides
(LPS) as observed in infected/untreated (white columns) and infected/
treated mice (black columns). Values after three and four cycles of
treatment and after 8 weeks of treatment interruption (3rd cycle8 and
4th cycle8) are reported. Spleen lymphocytes were tested for 3[H]thy-
midine incorporation after 3 days of culture with LPS. At the end of the
4th cycle (16 weeks p.i.) the values of only two infected animals are
reported because three mice had died as a consequence of the
infection. At 3rd cycle8 and 4th cycle8 the values relative to the
infected/untreated mice are not reported since all animals had died.
CPM values standard deviation in the control animals were 34,232
7000 (per 106 cells) at the 3rd cycle, 32,840 9200 (per 106 cells) at the
4th cycle, 50,900 11,000 at the 3rd cycle8, and 35,325 8500 at the
4th cycle8.
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than that observed in spleen and bone marrow from
infected/untreated animals, it is likely sufficient to induce
the rebound of diffuse viral replication that we have
observed after 8 weeks of treatment interruption. We
have also determined the total organ (spleen and lymph
nodes) proviral DNA load in each infected and infected/
treated animal. To do this, we have measured the weight
of the spleen and lymph nodes and then multiplied by the
proviral DNA content per mg of tissue examined. As
shown in Table 3, four cycles of alternate Fludarabine
and AZT plus DDI reduced the proviral DNA load in the
spleen to 3.5–4.5% of the amount found in the infected/
untreated animals. When this estimate is done for the
lymph nodes of the single/treated mouse for which a
proviral DNA detection is measurable, this value is even
lower, reaching 0.044–0.1% of the untreated mice.
In all, these results suggest that the spleen and bone
marrow may act as anatomic reservoirs for LP-BM5 in-
fection at a time when our treatment protocol has in-
duced near-complete suppression of proviral load in
lymph nodes.
DISCUSSION
Analyses of the HAART-induced rates of HIV decay in
infected patients have been used to estimate the time
necessary to achieve eradication of the infection. If the
assumption is made that initial replication is completely
suppressed by HAART and no reservoirs of chronically
infected, long-lived cells are present, these analyses
suggested that eradication of HIV infection may be
achieved after 1–3 years of treatment (Perelson et al.,
TABLE 2
Suppression of BM5d Proviral DNA in Lymph Nodes of LP-BM5-Infected Mice After Alternate Administration of Fludarabine and AZT Plus DDI
Experimental group
BM5d proviral DNA copy numbera
Weeks postinfection (p.i.)
4 (1st cycle) 8 (2nd cycle) 12 (3rd cycle) 16 (4th cycle)
Untreated 14,840 4494 78,697 30,447 169,340 89,968 255,256; 126,079 (n  2)b
Treated 2754 1462 7482 2930 5467 5555 4985
(5018; 5350; 15,782; 885; 300) Undetectable in 4 mice
a Proviral DNA molecules per 40 ng of total cellular DNA, as assessed by a competitive PCR assay as described under Materials and Methods.
Values are shown as mean  standard deviation of five animals.
b Three animals died as a consequence of the infection.
FIG. 4. BM5d proviral load in lymph nodes of infected/untreated C57BL/6 mice (F) and infected/treated C57BL/6 mice (E). Forty nanograms of total
cellular DNA was used to perform a competitive PCR assay as described under Materials and Methods. At the end of the fourth cycle (16 weeks p.i.)
four of five infected/treated animals had undetectable proviral load. Also, at week 16 p.i. only two infected/untreated animals are reported because
three mice had died as a consequence of the infection. After 8 weeks of third- and fourth-cycle interruption (3rd cycle8, 20 weeks p.i.; 4th cycle8,
24 weeks p.i., respectively), the values relative to the infected/untreated mice are not reported since all animals had died.
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1997). Unfortunately, several cellular and anatomical res-
ervoirs for HIV-1 may contribute to long-term persistence
of virus despite long-term HAART. The direct longitudinal
analysis of the decay rate of latent but replication-com-
petent HIV-1 in resting CD4 T lymphocytes has indi-
cated that eradication of this reservoir may require over
60 years of treatment (Finzi et al., 1999). Furthermore,
increasing evidence (Igarashi et al., 2001; Lambotte et
al., 2000) suggests that other reservoirs, such as tissue
macrophages, play a role in maintaining HIV infection in
chronically treated patients and must be considered
when protocols aimed at eradicating HIV infection are
designed. The existence of these reservoirs represents
the main obstacle to eradication of HIV-1 with current
antiretroviral regimens and indicates that novel ap-
proaches to target the latent reservoirs are needed.
In a series of earlier studies we have investigated the
possibility of targeting the reservoirs of infection in a
mouse model of retroviral disease (i.e., MAIDS) by using
a combined therapeutic approach consisting of repeated
cycles of classical antiretroviral agents alternated with
the anticancer drug Fludarabine. We hypothesized that
Fludarabine may be particularly useful in targeting la-
tently infected cells that are not cycling and do not
support active viral production. Different mechanisms of
action can explain the observed effect of Fludarabine.
First, the drug could inhibit viral replication acting on
virus reverse transcriptase (RT). However this is not the
case because preliminary experiments in our laboratory
have shown that the concentration of Fludarabine 5-
triphosphate needed to inhibit the RT is too high to be of
pharmacological interest in our model. Second, Fludara-
bine could inhibit cell division as demonstrated by the
decrease of circulating B cells and as documented in a
number of in vivo studies (Keating et al., 1989, 1991).
Third, Fludarabine could specifically inhibit STAT 1 sig-
naling as we observed in previous studies in HIV-1-
infected macrophages (Balestra et al., 2000).
In this article we describe the results of a study using
repeated cycles of alternate administration of Fludara-
bine and two classical nucleoside analogues, AZT and
DDI. The main result of this study was the observation
that after four cycles of therapy the proviral DNA was
undetectable in the lymph nodes of four of five tested
animals. This result is of interest since in previous stud-
ies we had shown that the alternate administration of
Fludarabine and one nucleoside analogue (AZT) de-
creased proviral DNA content in lymph nodes by only
about 85% when compared to infected/untreated mice
(Fraternale et al., 2000a,b). Importantly, the antiviral effect
of alternate administration of Fludarabine and AZT plus
DDI was more pronounced than the effect of a 10-week
administration of AZT plus DDI that induced a decrease
in splenomegaly, lymphadenopathy, and hypergamma-
globulinemia of 63, 77, and 69%, respectively, and an
inhibition of the proviral DNA in lymph nodes of only 90%
when compared to infected/untreated animals (data not
shown). Moreover, the same treatment did not restore
the proliferative index of B and T cells (data not shown).
The efficacy of the presently described therapeutic pro-
tocol was further confirmed by the evaluation of its
marked effects on several other known markers of dis-
ease progression, including splenomegaly, lymphoad-
enopathy, hypergammaglobulinemia, changes in the pro-
file of lymphoid populations, and the defective prolifera-
tive response to LPS.
Unfortunately, the virtually complete suppression of
viral replication that we have observed in lymph nodes of
treated animals did not represent actual eradication of
the infection since proviral DNA was observed in the
lymph nodes after an 8-week period of therapy discon-
tinuation. Further studies of proviral DNA in other tissues
indicated that spleen and bone marrow cells might rep-
resent the source of the observed rebound of viral rep-
lication. Results obtained in other experiments per-
formed on the same animal model have shown that at
least a significant part of these latently infected cells
might be macrophages (Casabianca et al., 2001). Al-
though encouraging, our data clearly indicate that erad-
ication of infection in the LP-BM5 model of murine AIDS
TABLE 3
BM5d Proviral DNA in Spleen, Bone Marrow, and Lymph Nodes of LP-BM5-Infected Mice After Four Cycles
of Alternate Administration of Fludarabine and AZT Plus DDI
BM5d proviral DNA copy number/40 ng
cellular DNA
BM5d proviral DNA copy number
 106/mousea
Experimental group Spleen Bone marrow Lymph nodes Spleen Lymph nodes
Untreated (n  2)b 118,877; 137,168 14,695; 35,048 255,256; 126,079 1.1; 1.4 10; 22.5
Treated (n  5) 5338 1405 5575 486 4985 0.05 0.02 0.01
undetectable in 4 mice undetectable in 4 mice
Note. Proviral DNA copy number has been determined by using a competitive PCR assay as described under Materials and Methods.
a Values were obtained considering the weight of the spleen and total lymph nodes (mediastinal, inguinal, axillary, paramandibular, and mesenteric)
in every animal for which quantitative proviral DNA content was determined.
b Three animals died as a consequence of the infection. Treatment protocol is represented in Fig. 1.
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will require a more effective therapeutic strategy that
would successfully target the spleen and bone marrow
reservoirs. One possible option may be the administra-
tion of five or more cycles of Fludarabine and antiretro-
viral drugs, as perhaps suggested by the observation
that undetectable levels of proviral DNA in lymph node
are not consistently reached until between the third and
the fourth cycle of therapy. On the other hand, possible
toxicity problems should be considered, since prolonged
treatment with Fludarabine is known to induce marked
hypocellularity in the spleen and lymph nodes. Similarly,
after a critical number of cycles per unit of time, the
beneficial effect of Fludarabine and AZT plus DDI ther-
apy on the lymphocyte function of infected animals may
be outweighed by the lymphotoxic effects of Fludarabine.
A second possible option is to reduce the drug-related
toxicity by alternating cycles of different cytotoxic drugs
with cycles of antiretrovirals (i.e., one cycle of Fludara-
bine and AZT plus DDI followed by one cycle of 2-chloro-
2-deoxyadenosine and AZT plus DDI). A third possible
option is to use special drug-delivery systems, such as
liposomes or autologous red blood cells, that can induce
high levels of drug concentration in the specific micro-
environment of latently infected cells belonging to the
monocyte/macrophage lineage.
In summary, the results presented in this article sug-
gest that repeated cycles of Fludarabine and two potent
nucleoside analogues (AZT and DDI) may normalize the
parameters of disease progression in this model of mu-
rine AIDS to control values and may reduce the proviral
DNA content in lymph nodes to undetectable levels.
Although eradication of LP-BM5 infection was not
achieved and eventually reactivation of viral replication
was observed after therapy discontinuation, the results
of these experiments confirm that strategies based on
the combination of antiretroviral and cytotoxic drugs are
effective in suppressing the ongoing viral replication and
may represent a promising approach to target reservoirs
of latently infected cells.
MATERIALS AND METHODS
Viral stocks
The LP-BM5 viral mixture was kindly provided by Rob-
ert Yetter (Veterans Administration Hospital, Baltimore,
MD) and was maintained in a persistently infected SC-1
cell line, as previously described (Mosier et al., 1987).
Female C57BL/6 mice (Nossan, Milan, Italy) were in-
fected by means of two consecutive intraperitoneal in-
jections at 24-h intervals (1 IU RT). Mice were housed
at 22  1°C with a 12-h light/dark cycle, 60  5%
humidity, and 12 air changes/h.
Zidovudine and Didanosine
Zidovudine (AZT) and Didanosine (DDI) were from Sigma
(Milan, Italy). AZT and DDI were administered ad libitum in
drinking water at a concentration of 250 and 134 mg/L,
respectively, beginning 24 h after the first viral injection. AZT
and DDI were stable in the drinking water at room temper-
ature and the water was changed every 3 days.
Fludarabine
Fludarabine was provided by Schering A.G. Berlin,
Germany and was administered intraperitoneally at the
concentration of 0.15 mg/g twice a day for 5 days a week.
Serum immunoglobulin G (IgG) determination
Serum IgG levels were determined using an ELISA tech-
nique as previously described (Fraternale et al., 1999).
Flow cytometry analysis
Whole-blood samples were stained with fluorescein
isothiocyanate (FITC)-conjugated antimouse CD4 (L3T4)
(PharMingen, San Diego, CA) for the detection of CD4
lymphocytes, phycoerythrin (PE)-conjugated antimouse
CD8 (Sigma, Milan, Italy) for the detection of CD8a lym-
phocytes, FITC-conjugated antimouse CD90.2 (Thy-1)
(PharMingen, San Diego, CA) for the detection of T cells,
and PE-conjugated antimouse CD19 for the detection of
committed B cell precursors (PharMingen, San Diego,
CA). Samples were analyzed by FACS (Becton–Dickin-
son, San Jose, CA).
Competitive polymerase chain reaction analysis of
LP-BM5 proviral DNA
Total cellular DNA was isolated from lymph nodes,
spleen, and bone marrow of uninfected, infected, and in-
fected/treated mice and BM5d proviral DNA content was
quantified by a competitive PCR assay as previously de-
scribed (Casabianca et al., 1998). Briefly, competitive PCR
(cPCR) for proviral BM5d-DNA quantification consists of
coamplification of a fixed amount of the target gene (141 bp
of p12gag gene of BM5d genome; GenBank Accession No.
M64096) in the presence of a variable known copy number
of a DNA competitor (pMOS-106 plasmid) incorporating a
deletion in the target sequences and bearing the same
primer binding region. The two amplification products (141
and 106 bp) are clearly distinguishable by gel electrophore-
sis and their quantification is performed by measuring the
radioactivity associated with the respective band hybridized
with 32P-labeled D30 specific probe (Aziz et al., 1989) using
GS-250 molecular imager (Bio-Rad, Hercules, CA). The val-
ues obtained are plotted a function of the log10 of the known
competitor DNA copy number. The point of equivalence is
that at which the amounts of radioactivity incorporated into
the competitor and target were equal and represented the
number of copies of BM5d proviral DNA in the starting
sample.
The DNAs from organs of mice were coamplified with
different selected range of pMOS-106 competitor dilu-
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tions: 1  104, 5  104, 1  105, and 3  105 molecules
for infected mice and 1  102, 7.5  102, 2.5  103, and
1  104 molecules for infected/treated ones. The lowest
sensitivity limit of the method is 100 copies.
Lymphocyte proliferative index
3[H]Thymidine incorporation upon lymphocyte stimula-
tion by lipopolysaccharide for B cells was measured as
previously described (Rossi et al., 1992).
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